MiMedx Lifts Adjusted Net Sales Outlook for FY21
7:54AM ET 12/07/2021 MT NewswiresMiMedx Group, Inc (MDXG) said Tuesday it now expects adjusted net sales for the fiscal year 2021 to be between $253 million and $258 million, higher than...
Quotes Snapshot > MDXG
MiMedx Group Inc MDXG:NASDAQ
Last Price$5.12NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/14/22
Today's Change+0.08(1.59%)
Bid (Size)$5.11 (41)
Ask (Size)$5.12 (247)
Day Low / High$4.80 - 5.14
Volume750.5 K
Read more news Recent News
Top Premarket Decliners
8:16AM ET 11/26/2021 MT NewswiresMiMedx Group (MDXG) shares slumped 21% following a muted session. Pinduoduo (PDD) shares fell 19% even after the company posted improved Q3 earnings...
-- Earnings Flash (MDXG) MIMEDX GROUP Posts Q3 Revenue $63.1M, vs. Street Est of $60.3M
4:51PM ET 11/02/2021 MT Newswires...
HC Wainwright Adjusts Price Target for MiMedx Group to $8.50 From $20, Maintains Buy Rating
10:16AM ET 9/14/2021 MT NewswiresMiMedx Group, Inc (MDXG) has an average investment rating of buy among analysts polled by Capital IQ, with a price target range of $17 to $23. (MT...
View all Commentary and Analysis
MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q3 2021 Results - Earnings Call Transcript
3:45PM ET 11/03/2021 Seeking AlphaMy 31-Stock $379k Retirement Portfolio Has A September Swoon
10:08AM ET 10/01/2021 Seeking AlphaWall Street Breakfast: What Moved Markets
6:38AM ET 9/18/2021 Seeking AlphaMy 32 Stock Retirement Portfolio Breaks $400,000 In August
1:31PM ET 9/01/2021 Seeking AlphaCompany Profile
Business DescriptionMiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane; EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matri derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA. View company web site for more details
| Address | 1775 West Oak Commons Court NE Marietta, Georgia 30062 |
| Phone | +1.770.651.9100 |
| Number of Employees | 690 |
| Recent SEC Filing | 01/10/2022 8-K |
| Chief Executive Officer & Director | Timothy R. Wright |
| Senior Vice President-Operations & Procurement | Scott M. Turner |
| Chief Financial Officer | Peter M. Carlson |
| Chief Medical Officer | David H. Mason |
Company Highlights
| Price Open | $5.00 |
| Previous Close | $5.04 |
| 52 Week Range | $4.80 - 15.99 |
| Market Capitalization | $574.2 M |
| Shares Outstanding | 112.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/14/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.31 |
| Beta vs. S&P 500 | N/A |
| Revenue | $245.0 M |
| Net Profit Margin | -11.20% |
| Return on Equity | -33.48% |
Analyst Ratings as of 07/23/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |